Clinical trials: Age Factor
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Age Factor, Age-related Macular Degeneration
Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance Levels
The objective of this study is to determine which luminance levels yield maximum differences in critical flicker fusion (CFF) scores between younger and older normal subjects.
- Trial name
- NCT03079570
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Healthy Volunteers (Middle-aged Smokers)
Effects of Curcumin on Vascular Reactivity
The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
- Trial name
- CURCUMIN (NCT01543386)
- Testing
- Curcumin
- Where
- France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Age Related Macular Degeneration
Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial.
- Trial name
- NCT01626339
- Testing
- Intravitreal Ranibizumab, Intravitreal bevacizumab
- Where
- Malaysia
- Volunteers
- 30 people
- Sponsor
- University of Malaya
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Hemophilia A
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
Hemophilia A is an inherited blood disorder in which one protein, Factor VIII, needed to form blood clots is missing or not present in sufficient levels.
- Trial name
- NCT01775618
- Testing
- BAY94-9027
- Where
- 37 sites in United States, Argentina and 15 more
- Volunteers
- 73 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging.
- Trial name
- NCT00344227
- Testing
- Lucentis (Ranibizumab)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Wet Macular Degeneration
Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse
Age-related macular degeneration (AMD) is a chronic and progressive eye disease and is one of the leading causes of vision impairment globally.
- Trial name
- NCT05211804
- Testing
- Ophthalmic Drugs
- Where
- Norway
- Volunteers
- 31 people
- Sponsor
- Sorlandet Hospital HF
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
- Trial name
- NCT05146687
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 369,600 people
- Sponsor
- Novartis Pharmaceuticals
Frailty, Septic Shock
Evaluation of the Clinical Frailty Scale (CFS) as a Risk Factor of Mortality in Adult Patients ≤65 Years of Age Admitted to Intensive Care for Septic Shock.
The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14)…
- Trial name
- Woodstock (NCT05928767)
- Where
- 5 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de Lens
Congestive Heart Failure
Study to Evaluate the Safety of Twice Daily Oral Carvedilol
The objective of this study is to evaluate the long-term safety of carvedilol in pediatric patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321.
- Trial name
- NCT00129363
- Testing
- Carvedilol
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Shaddy, Robert, M.D.
Phenylketonuria
Effect of L-carnitine Supplementation on Phenylalanine and Brain-derived Neurotrophic Factor Levels in Infants and Children With Phenylketonuria
Effect of L-carnitine supplementation on phenylalanine and brain-derived neurotrophic factor levels in infants and children with phenylketonuria L-carnitine is mainly obtained from foods such as red meat and milk that are limited…
- Trial name
- NCT06901323
- Testing
- L-carnitine
- Where
- Egypt
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Sleep Disorders
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances
The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT).
- Trial name
- NCT00000380
- Testing
- GHRH
- Sponsor
- University of Washington
Age-Related Macular Degeneration
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)
Age-Related Macular Degeneration (ARMD) is the most common cause of blindness in the adult population of the Western World. It affects the macula - the region of the retina most rich in photoreceptors and responsible for central…
- Trial name
- NCT02762188
- Testing
- Genotype analysis
- Where
- Belgium
- Volunteers
- 501 people
- Sponsor
- Brugmann University Hospital
Bronchopulmonary Dysplasia, Vitamin D Overdose
25OH Vitamin D Overdoses and Risk of Bronchopulmonary Dysplasia or Death
Several studies have demonstrated that vitamin D deficiency at birth is a risk factor of bronchopulmonary dysplasia. However, in an animal model of bronchopulmonary dysplasia vitamin D overdose has also been associated with an…
- Trial name
- 25OHVDORBPDD (NCT05944055)
- Testing
- Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?
- Where
- France
- Volunteers
- 173 people
- Sponsor
- Hospices Civils de Lyon
Age-related Muscle Decline
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding…
- Trial name
- CALM-AF-AI (NCT07443826)
- Testing
- AAV9-Follistatin gene therapy, VEGF Plasmid
- Where
- Honduras
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Unlimited Biotechnology LLC
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Wet Macular Degeneration
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01249937)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Hypertension, Stroke
Culturally Tailoring a Stroke Intervention in Community Senior Centers
Stroke is a cruel disease that disproportionately kills and disables African-Americans, Latinos, Chinese-Americans and Korean-Americans; seniors with high blood pressure are at particularly high risk.
- Conditions
- Hypertension, Stroke, Sedentary Lifestyle, Aged
- Trial name
- SPIRP (NCT02181062)
- Testing
- Walking Intervention
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of California, Los Angeles
Neovascular Age-Related Macular Degeneration
A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1M, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth…
- Trial name
- NCT03387566
- Testing
- HB002.1M
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Huabo Biopharm Co., Ltd.